Siren Sezer1, Bahar Gurlek Demirci1, Mehtap Erkmen Uyar1, Saliha Uyanik2 and. Mehmet Haberal3. 1Baskent University Faculty of Medicine, Department of ...
Feb 10, 2018 - FIBROBLAST GROWTH FACTOR23. Zhimin Chen1,2 ... 1Karolinska Institutet, Renal department, Stockholm, SWEDEN, 2Zhejiang. University ...
Oct 7, 2017 - CALCIFICATION AND SERUM FETUIN-A LEVELS IN RENAL. TRANSPLANT RECIPIENTS. Ismail Kocyigit1, Aydin Unal1, Deniz Elcik2, Hafsa ...
Apr 10, 2014 - ... or small vessel thrombosis in any tissue or organ or pregnancy morbidity. ..... orders, as myasthenia or pemphigus, includes corticosteroids,.
KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED. PATIENTS. Erika De ... transplant unit. Rate of rejection and graft ... transplant glomerulopathy. However ...
(AMR) and mix type respectively. Type of acute rejections according to banff classification were given in table 2. 43 (67.2 %) acute rejection episode were in first ...
ity of life, productivity and growth of children and longer patient survival than what can be achieved by any modality of long-term dialy- sis [2,3]. Graft survival has ...
Although anatomi- cal factors ..... nal problems. There are still uneasy questions regarding ... tus, risk of recurrence of primary disease and psychosocial status ...
Oct 18, 1976 - ing 0.005 M Veronal (Winthrop Laboratories, Sterling Drug. Co., New York) and 0.1 M NaCl, followed by 100 ng. 125I-Clq. This mixture was ...
1University Hospitals Birmingham NHS Foundation Trust, Department of ... female gender, White ethnicity and a history of pre-transplant diabetes mellitus or.
islet transplantation (CIT) can permit T1DM individuals to achieve stable ..... degree of chronic microvascular damage due to diabetes may predispose to ...
Mar 20, 2013 - 2 The Regional Center of Excellence for Transplantation and Kidney Care, Erie County Medical Center, 462 Grider Street,. Buffalo, NY 14215 ...
Lao A, Bach D. Colonic complications in renal transplant. Colon Rectum 1986; 29
: 99. 19. Strodel WE, Dent TL, Nostrant TT, Eckhauser FE, Campbell recipients.
not convincingly been shown to slow or reverse chronic CNI toxicity [9â11]. Although the short- term reports on belatacept appear more promising, the long-term ...
Sep 23, 2004 - The relationships between blood pressure and kidney transplant recipients are complex. As more patients now reach end-stage kidney disease ...
Jul 27, 2007 - Baluarte HJ, Gruskin AB, Ingelfinger JR, Stablein D, Tejani A. (1994) Analysis of hypertension ... Jacobi J, Rockstroh J, John S, Schreiber M, Schlaich MP,. Neumayer HH, Schmieder .... Kahan BD, Flechner SM, Lorber MI, Golden D, Conley
Oct 9, 2018 - cell by manual and automated technique followed by amplification. The final nucleic acid ..... Am 9: 1045. 12. Fishman JA (2007) Infection in ...
Nephrol Dial Transplant (1998) 13: 1285â1287. Nephrology. Dialysis. Transplantation. Case Report. Ogilvie's syndrome following renal transplantation.
1, pp. 69â76, 1986. [6] A. Savar, J. R. Hiatt, and R. W. Busuttil, âAcute appendicitis after ... Howard, Eds., Appleton-Century-Crofts, New York, NY, USA,. 1982.
Background. Thrombotic thrombocytopenic purpura/ haemolytic-uraemic syndrome (TTP/HUS) is a rare cause of renal failure in adults. There is little data.
complicated by septic shock and multiple organ failure, including acute renal injury ..... John GT, Shankar V, Abraham AM, Mukundan U, Thomas PP, Jacob CK.
Powis SJA, BARNES AD, DAWSON-. EDWARDS P, et al: Ileocolonic prob- lems after cadaveric renal transplanta- tion. Br Med J 1: 99, 1972. 38. DEMLING RH ...
Mar 19, 2013 - (CML) patients.1â3 To date, only one case of imatinib-induced thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome (TTP/HUS) ...
Introduction and Aims: There is no active treatment for post-renal transplant BK virus associated nephropathy (BKVAN) that has proven to be effective so far.
LONG TERM FOLLOW UP OF ACTIVE MANAGEMENT VERSUS MINIMIZATION OF IMMUNOSUPPRESSIVES OF BK VIRUS ASSOCIATED NEPHROPATHY AFTER A KIDNEY TRANSPLANT
Medhat Abdel Halim1, Torki Al-Otaibi1, Osama Gheith1, Ahmed Mosaad1, Zakaria Zakaria1, Tarek Said1, Prasad Nair1 and Mrn Nampoory1 1 Ibn Sina Hospital, Medical, Kuwait, Kuwait Introduction and Aims: There is no active treatment for post-renal transplant BK virus associated nephropathy (BKVAN) that has proven to be effective so far. We aimed to assess effectiveness of active management of BKVAN with combined leflunomide, IVIG and ciprofloxacin on the long term graft outcome compared to minimization of immunosuppressives. Methods: Our kidney transplant recipients were screened for BKVAN. Group1 (n=22): was composed of kidney transplant recipients with twice positive BK virus-PCR in
urine and blood who underwent graft biopsy to confirm BKVAN. Once BKVAN is diagnosed, anti-metabolite (mycophenolate mofetil or azathioprine) was changed to leflunomide and a course of IVIG and oral ciprofloxacin were given. Group 2(n=33): was composed of BKVAN patients treated conventionally with reduced immunosuppressives. Results: Fifty five patients were treated, 69%were males, 50.9% were diabetics, mean HLA mismatches was 3.65 and 50.9% of patients were CW7 negative. All patients received induction therapy (thymoglobulin in 55.6%) and 52.7% received antirejection therapy before BKVAN diagnosis. Maintenance immunosuppression was prednisolone (96.3%), mycophenolate mofetil (94.5%) and tacrolimus (50.9%). Subsequent rejection episodes have occurred in 38% of the patients after BKVAN diagnosis. Basal mean eGFR was 52.5±25.5 which has reduced significantly to 38.1±27.8 ml/min/1.73m2 ( p
